Skip to content

ALAnostics passed Venture Kick round 1

ALAnostics, a spin-off of the University of Geneva that participated in SCM ’18 (Bern), develops a tumor paint that helps surgeons identify breast cancer cells during surgery. This ensures that as little as possible healthy tissue but all of the tumour is removed during surgery. With its technology, ALAnostics can minimize the risk of additional operations and improving the survival rate of breast cancer patients.